Burlando Martina, Salvi Ilaria, Parodi Aurora, Cozzani Emanuele
Division of Dermatology, Department of Health Sciences-DISSAL, University of Genoa, Genoa, Italy.
IRCCS Policlinic Hospital San Martino, Largo Rosanna Benzi X, 16132, Genoa, Italy.
Dermatol Ther (Heidelb). 2024 Sep;14(9):2645-2652. doi: 10.1007/s13555-024-01252-7. Epub 2024 Aug 27.
The efficacy and safety of tildrakizumab for the treatment of plaque psoriasis were demonstrated by randomized clinical studies, but the reappraisal of prolonged experiences in the clinical practice helps to optimize the use of this biologic drug. The aim of this study was to evaluate the long-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis in the real world.
This is a long-term retrospective observational study in a real-life setting. Overall, 136 adult patients with moderate-to-severe plaque psoriasis and treated with tildrakizumab were included.
One hundred percent reduction of Psoriasis Area Severity Index (PASI100) was reached by 21.7% of patients at 4 weeks of therapy and by 51.2% at week 16, and the proportion of patients with this improvement was between 66.9% and 64.5% from 36 weeks to 3 years. The mean PASI of the cohort progressively improved from 12.6 at baseline to 1.8 at week 36 and was stable at 1 year, 2 years and 3 years. We could not confirm a previous observation that patients naïve to biologic had a better response, but we observed that those with a short history of psoriasis had a higher probability of 90% PASI reduction (PASI90) or PASI 100 within 36 weeks, suggesting that early treatment could be useful.
This long-term observation in the real life of patients with moderate-to-severe plaque psoriasis receiving tildrakizumab 100 mg showed that PASI100 can be obtained in a high proportion of patients by week 36 and be maintained for up to 3 years.
随机临床研究证明了替拉珠单抗治疗斑块状银屑病的疗效和安全性，但对临床实践中长期经验的重新评估有助于优化这种生物药物的使用。本研究的目的是评估替拉珠单抗在现实世界中对中度至重度银屑病患者的长期疗效。
这是一项在现实生活环境中的长期回顾性观察研究。总共纳入了136例接受替拉珠单抗治疗的中度至重度斑块状银屑病成年患者。
21.7%的患者在治疗4周时达到银屑病面积和严重程度指数（PASI）100%改善，16周时这一比例为51.2%，从36周持续至3年，实现这一改善的患者比例在66.9%至64.5%之间。该队列的平均PASI从基线时的12.6逐步改善至36周时的1.8，并在1年、2年和3年时保持稳定。我们无法证实之前观察到的未使用过生物制剂的患者反应更好这一现象，但我们观察到银屑病病程短的患者在36周内有更高概率实现90%PASI改善（PASI90）或PASI 100，这表明早期治疗可能有益。
对100mg替拉珠单抗治疗的中度至重度斑块状银屑病患者的这一长期现实生活观察表明，到36周时，高比例患者可实现PASI100，并维持长达3年。
